Thor Medical ASA - Completed primary insider purchases after option exercise

02 Mar 2026 19:41 CET

2.3.2026 19:41:34 CET | Thor Medical ASA | Mandatory notification of trade
primary insiders

Oslo, Norway, 2 March 2026 - Reference is made to the stock exchange
announcement made by Thor Medical ASA on 27 February 2026 regarding the exercise
of share options. The primary insiders of the Company have purchased additional
shares in the Company following the cash less option exercise.

Notifications of the transaction in accordance with the Market Abuse Regulation
article 19 are attached to this announcement.

The purchases of shares have been funded by an initial sale of borrowed shares
in the market as customary for cashless exercise structures. The sales were
completed at an average price of NOK 4.0766 per share. All primary insiders have
utilized the after- tax gain from the option program to buy new shares and
increased their investment in the company at the sales price.

In addition to the shares acquired in the cash less exercise, the above primary
insiders exercised options and subscribed a total of 1,600,000 shares as
announced on 27 February 2026. In the option exercise, the primary insiders of
the Company have increased their shareholding as follows:

* Jasper Kurth, CEO, 1,152,698 shares;
* Brede Ellingsæter, CFO & COO, 676,055 shares;
* Sindre Hassfjell, CTO, 825,001 shares; and
* Astrid Liland, EVP HSEQ, 518,372 shares.

The cashless exercise of options has been facilitated through a share lending
arrangement with Scatec Innovation AS, a close associate of the Company's chair
of the board, John Andersen. Notifications of the share lending in accordance
with the Market Abuse Regulation article 19 are attached to this announcement.

For further information please contact:

Mathias Nilsen Reierth
Head of Communications and Corporate Affairs
Tel: +47 988 05 724
mathias.reierth@thormedical.com



ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of alpha particle emitters produced from
naturally occurring thorium. Its proprietary production process requires no
irradiation or use of nuclear reactors, and provides reliable, environmentally
friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical
industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange under the ticker symbol 'TRMED'. To learn more, visit
www.thormedical.com - http://www.thormedical.com - http://www.thormedical.com.



This information is subject to the disclosure requirements pursuant to the
Market Abuse Regulation article 19 and section 5-12 of the Securities Trading
Act.



ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18820866/6862/Download%20announce
ment%20as%20PDF.pdf

20260302 - TRMED - MAR purchase of shares - primary insider notification.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18820866/6860/20260302%20-%20TRME
D%20-%20MAR%20purchase%20of%20shares%20-%20primary%20insider%20notification.pdf

20260302 - TRMED - MAR share lending - primary insider notification.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18820866/6861/20260302%20-%20TRME
D%20-%20MAR%20share%20lending%20-%20primary%20insider%20notification.pdf

More information:
Access the news on Oslo Bors NewsWeb site

667305_Download announcement as PDF.pdf
667305_20260302 - TRMED - MAR purchase of shares - primary insider notification.pdf
667305_20260302 - TRMED - MAR share lending - primary insider notification.pdf